DCTH Delcath stock news
As of June 27, 2026, Delcath Systems Inc. (DCTH) maintains a "Strong Buy" consensus rating among Wall Street analysts. The consensus price target is established at $22.00, suggesting a substantial upside from the current market price of approximately $12.40. This positive sentiment is driven by the company's continued commercial rollout of the HEPZATO KIT and its expanding network of active treatment centers.